Danil V. Osintsev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danil V. Osintsev has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akhmetzhanova D.O.
НАО «Медицинский университет Семей
2 shared publications - Anastasia V. Batyarkina
ФГБОУ ВО «Алтайский государственный медицинский университет» Министерства здравоохранения Российской Федерации
2 shared publications - Bogdan S. Roy
Altai State Medical University, Barnaul
2 shared publications - Nikolay A. Dorokhov
Altai State Medical University
2 shared publications - Anna V. Suvorova
Altai State Medical University, Barnaul
1 shared publication - D. G. Polukhin
КГБУЗ «Детская городская клиническая больница №7, г. Барнаул
1 shared publication
Latest Publications
- Open Access
- 21 June 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 2,p. 135-138
A clinical case in pediatric practice: mitochondrial DNA depletion syndrome, type 2 (myopathic form)
The paper discusses the diagnosis and treatment of mitochondrial DNA depletion syndrome (MDS), which is associated with a defect in the thymidine kinase 2 (TK2) gene. Despite the expansion of neonatal screening (up to 36 diseases, with plans to increase it to 62), the detection of MDS requires expensive whole-genome sequencing and is not yet available on a large scale. A case of a girl with TC-2-associated mitochondrial myopathy is described: the disease manifested itself at 9 months with weakness of the limbs and regression of motor skills, complicated by pneumonia, respiratory failure and cardiomyopathy. The diagnosis was confirmed genetically. The patient received therapy with deoxytimidine and deoxycytidine — the condition stabilized, new skills appeared. Long-term follow-up showed a decrease in the frequency of pneumonia, improvement of tests and a decrease in dependence on respiratory support. The importance of early genetic diagnosis and access to treatment is emphasized; research centers and telemedicine can help with this.
- 21 June 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 2,p. 135-138
Open AccessA clinical case in pediatric practice: mitochondrial DNA depletion syndrome, type 2 (myopathic form)
The paper discusses the diagnosis and treatment of mitochondrial DNA depletion syndrome (MDS), which is associated with a defect in the thymidine kinase 2 (TK2) gene. Despite the expansion of neonatal screening (up to 36 diseases, with plans to increase it to 62), the detection of MDS requires expensive whole-genome sequencing and is not yet available on a large scale. A case of a girl with TC-2-associated mitochondrial myopathy is described: the disease manifested itself at 9 months with weakness of the limbs and regression of motor skills, complicated by pneumonia, respiratory failure and cardiomyopathy. The diagnosis was confirmed genetically. The patient received therapy with deoxytimidine and deoxycytidine — the condition stabilized, new skills appeared. Long-term follow-up showed a decrease in the frequency of pneumonia, improvement of tests and a decrease in dependence on respiratory support. The importance of early genetic diagnosis and access to treatment is emphasized; research centers and telemedicine can help with this.
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (3) , 106-111
X-LINKED CENTRONUCLEAR MYOPATHY: A CLINICAL CASE IN A PEDIATRICIAN'S PRACTICE
X-linked myotubular myopathy (X-МTM) is a serious and potentially fatal myopathy resulting from a mutation in the myotubularin (MTM1) gene. The primary clinical features include widespread muscle weakness, early-onset hypotension, and respiratory failure, along with various associated conditions that frequently lead to mortality. The authors present a clinical case involving a 3.5-year-old boy diagnosed with X-linked myotubular myopathy. This patient was monitored from the age of 11 months, with the diagnosis confirmed at 1.4 years through whole-genome sequencing. A novel nonsense mutation in exon 7 of the MTM1 gene was discovered, which is responsible for the onset of X-linked myotubular myopathy. The mutation in the myotubularin (MTM1) gene disrupts the normal development and functioning of myocytes, resulting in a distinct triad of symptoms: widespread muscle weakness, neonatal hypotonia, and respiratory failure. Furthermore, several additional features typical of X-linked myotubular myopathy have been identified: physical characteristics (such as dolichocephaly, arachnodactyly, elongated limbs, and tall stature), cryptorchidism, joint contractures, dysphagia accompanied by weakness in the swallowing muscles, psychomotor retardation, peliosis hepatis, and progressive ophthalmoplegia. X-linked myotubular myopathy can result in severe, life-threatening complications, highlighting the critical need for early diagnosis and intervention. Given the infrequency of this condition, the potential for de novo mutations in the gene, and the extensive differential diagnosis that includes both myopathies and bronchopulmonary disorders, it is vital to gather clinical data on X-linked myotubular myopathy. Consequently, it is imperative to engage clinicians and establish protocols for the early detection of myopathy within the first year of life to reduce the risks associated with delayed diagnosis and management errors.
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (3) , 106-111
X-LINKED CENTRONUCLEAR MYOPATHY: A CLINICAL CASE IN A PEDIATRICIAN'S PRACTICE
X-linked myotubular myopathy (X-МTM) is a serious and potentially fatal myopathy resulting from a mutation in the myotubularin (MTM1) gene. The primary clinical features include widespread muscle weakness, early-onset hypotension, and respiratory failure, along with various associated conditions that frequently lead to mortality. The authors present a clinical case involving a 3.5-year-old boy diagnosed with X-linked myotubular myopathy. This patient was monitored from the age of 11 months, with the diagnosis confirmed at 1.4 years through whole-genome sequencing. A novel nonsense mutation in exon 7 of the MTM1 gene was discovered, which is responsible for the onset of X-linked myotubular myopathy. The mutation in the myotubularin (MTM1) gene disrupts the normal development and functioning of myocytes, resulting in a distinct triad of symptoms: widespread muscle weakness, neonatal hypotonia, and respiratory failure. Furthermore, several additional features typical of X-linked myotubular myopathy have been identified: physical characteristics (such as dolichocephaly, arachnodactyly, elongated limbs, and tall stature), cryptorchidism, joint contractures, dysphagia accompanied by weakness in the swallowing muscles, psychomotor retardation, peliosis hepatis, and progressive ophthalmoplegia. X-linked myotubular myopathy can result in severe, life-threatening complications, highlighting the critical need for early diagnosis and intervention. Given the infrequency of this condition, the potential for de novo mutations in the gene, and the extensive differential diagnosis that includes both myopathies and bronchopulmonary disorders, it is vital to gather clinical data on X-linked myotubular myopathy. Consequently, it is imperative to engage clinicians and establish protocols for the early detection of myopathy within the first year of life to reduce the risks associated with delayed diagnosis and management errors.